Article
Does the bleomycin sensitivity assay express cancer phenotype?
Mutagenesis - 1 Jan 2003
Székely Gábor, Remenár Eva, Kásler Miklós, Gundy Sarolta
Abstract excerpt
The bleomycin (BLM) sensitivity assay has been associated with the measuring of increased risk of individual susceptibility to cancer, when chromatid breaks per cell (b/c) induced by an in vitro treatment of lymphocytes with BLM are elevated. The high heritability of BLM sensitivity indicates a genetic background. We wished to clarify whether the test characterizes the head and neck cancer phenotype as compared...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
